Change in Splenic Volume as a Surrogate Marker for Immunotherapy Response in Patients with Advanced Urothelial and Renal Cell Carcinoma—Evaluation of a Novel Approach of Fully Automated Artificial Intelligence Based Splenic Segmentation

Background: In the treatment of advanced urothelial (aUC) and renal cell carcinoma (aRCC), biomarkers such as PD-1 and PD-L1 are not robust prognostic markers for immunotherapy (IO) response. Previously, a significant association between IO and a change in splenic volume (SV) was described for sever...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Gregor Duwe, Lukas Müller, Christian Ruckes, Nikita Dhruva Fischer, Lisa Johanna Frey, Jan Hendrik Börner, Niklas Rölz, Maximilian Haack, Peter Sparwasser, Tobias Jorg, Christopher C. M. Neumann, Igor Tsaur, Thomas Höfner, Axel Haferkamp, Felix Hahn, Rene Mager, Maximilian Peter Brandt
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2023-09-01
coleção:	Biomedicines
Assuntos:	advanced urothelial carcinoma advanced renal cell carcinoma immunotherapy immune checkpoint inhibitor prognostic marker predictive marker
Acesso em linha:	https://www.mdpi.com/2227-9059/11/9/2482
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!